Format

Send to

Choose Destination
Clin Neurol Neurosurg. 2018 Sep;172:112-115. doi: 10.1016/j.clineuro.2018.07.003. Epub 2018 Jul 5.

Loss of MycBP may be associated with the improved survival in 1P co-deletion of lower grade glioma patients.

Author information

1
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, United States. Electronic address: steven.lehrer@mssm.edu.
2
Severn Health Solutions, Severna Park, MD, United States.
3
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, United States.

Abstract

OBJECTIVES:

The chromosome 1p/19q co-deletion is a favorable prognostic factor in patients with low grade glioma. In the current analysis, we examined MycBP expression in low grade glioma. MycBP lies on chromosome 1p.

PATIENTS AND METHODS:

We evaluated the association between MycBP and overall survival in the TCGA Lower Grade Glioma (LGG) dataset in TCGA (The Cancer Genome Atlas).

RESULTS:

Loss of MycBP copy number segment expression coincides with co-deletion of 1 P. The deleterious effect of MycBP on survival is significant (p = 0.00006306, hazard ratio 2.02, 95% CI 1.4-2.9). Patients with astrocytoma have the poorest survival of low grade glioma patients. MycBP mRNA is significantly overexpressed in astrocytomas when compared to normal brain (2.156 fold change, p = 0.0000488).

CONCLUSION:

Our report that Chromosome 1 P co-deletion may confer better survival in patients with lower grade glioma in part because of loss of MycBP corroborates other studies of the importance of MycBP in glioma development. Further work with microRNAs may lead to new treatments.

KEYWORDS:

Glioma; Myc; The Cancer Genome Atlas

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center